HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC. by 諛뺤콈洹�
HIV gag protein is efficiently cross-presented when targeted with
an antibody towards the DEC-205 receptor in Flt3 ligand-
mobilized murine dendritic cells
Leonia Bozzacco1, Christine Trumpfheller1, Yaoxing Huang2, Maria Paula Longhi1, Irina
Shimeliovich1, Joseph D. Schauer1, Chae Gyu Park1, and Ralph M. Steinman1
1Laboratory of Cellular Physiology and Immunology and Chris Browne Center, The Rockefeller
University, New York, NY, 10065-6399, USA
2 The Aaron Diamond AIDS Research Center, New York, NY, USA
Summary
Dendritic cells present exogenous proteins to MHC class I restricted CD8+ T cells. This function
does not require endogenous antigen synthesis within DC, providing the potential to elicit CD8+ T
cell responses to immune complexes, inactivated microbes, dying cells and proteins like
ovalbumin. In mice, the CD8+ or DEC-205+ DC are specialized for cross-presentation, and this
subset can be increased 10 fold in numbers following Flt3L treatment in vivo. Therefore we
studied cross-presentation by abundant Flt3L DC using HIV gag protein. When enriched by
positive selection with anti-CD11c beads, cells from Flt3L mice are not only more abundant but
are more highly enriched in CD11c high DC, particularly the DEC-205+ subset. DC cross-present
HIV gag to primed CD8+ T cells, but when the antigen is delivered within an antibody to
DEC-205 receptor, cross-presentation becomes 100 fold more efficient than non-targeted antigen.
This finding requires gag to be engineered into anti-DEC antibody, not just mixed with antibody.
Flt3L DC are a valuable tool to study cross-presentation, since their use overcomes the obstacle
posed by the low number of cross-presenting DC in the steady state. These findings support future
experiments to use Flt3L to enhance presentation of DC-targeted vaccines.
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Introduction
Induction of strong CD8+ T cell responses is a major goal in the development of preventive
and therapeutic vaccines against persistent viruses and tumors. Dendritic cells (DC) can
initiate CD8+ T cell responses through either direct priming or cross-priming. Direct priming
refers to the generation of peptide-MHC class I complexes from endogenously synthesized
proteins, while cross-priming involves processing of exogenous proteins acquired from the
extracellular environment. Cross-priming has been shown to be important in initiating MHC
class I- restricted responses to tumors, peripheral self, viral and bacterial antigens [1].
The efficiency of cross-presentation can be enhanced when dendritic cells (DC) take up
antigens through different receptor-mediated pathways particularly antigen-antibody
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complexes [2-4], dying cells [5,6], and proteins targeted within antibodies to specific
receptors like DEC-205 [7], DC-SIGN [8], MMR [9]; Langerin [10], LOX1 [11], and
CLEC9A [12]. In our research, we have been studying cross-presentation by genetically
engineering the sequences for protein antigens into the heavy chain of monoclonal
antibodies (mAb) to DC receptors, particularly DEC-205 [7].
Much of the research in this field has used ovalbumin (OVA) as a tool and the CD8+ OT-I
TCR transgenic line specific for OVA presented on H-2Kb molecules. This is because the
SIINFEKL peptide from OVA is presented efficiently, with only picomolar levels of peptide
being active when DC are the antigen presenting cells [13]. Nevertheless, DC can cross-
present other proteins like malaria circumsporozoite protein [13-16], HIV gag [17,18], HSV
and influenza proteins [19-21], and tumor antigens [12,22-24], although this cross-
presentation is often studied with TCR transgenic T cells. Vaccine science requires that the
cross-presentation pathway be extended to candidate vaccine antigens and non-transgenic T
cells.
In mouse lymphoid tissues, a subset of DC, marked by expression of CD8α homodimer and
the DEC-205/CD205 endocytic receptor, is more active in cross-presentation [4,6,25]. Here
we have studied these cross-presenting DC using mice exposed to Flt3L, which is known to
expand several different subsets of DC including a relatively high proportion of CD8+ DC,
increasing total numbers of this subset ∼ 30 fold [26,27].
With the most commonly studied protein, OVA, concentrations higher than 50 μg/ml of
protein are required to detect cross-presentation [9,13,25,28-34]. Here we test whether cross-
presentation of an exogenous HIV protein antigen, the gag p24 protein, to primed CD8+ T
cells can be enhanced by receptor mediated uptake. We will show that Flt3L DC efficiently
cross-present HIV gag via the DEC-205 receptor, about 100 times more effective than non-
targeted gag. 0.1 μg/ml of anti-DEC gag is as effective as 25 μg/ml of gag, suggesting that
this strategy for increasing DC numbers be used to identify cross-presentation mechanisms
and improve protein vaccines.
Results
Expansion and ready enrichment of CD11c+ DC from mice harboring a Flt3L expressing
B16 melanoma
We used anti-CD11c coated magnetic beads to enrich splenic CD11c+ DC from CxB6F1
mice injected with B16 Flt3L secreting melanoma cells. As previously reported, Flt3L
greatly expanded total DC numbers ∼10 fold [26,35,36]. In our experiments 4-5 ×106 cells
were isolated with anti-CD11c beads from one spleen of an untreated mouse, whereas ∼
60-70 ×106 cells could be enriched from the spleen of a mouse harboring a growing B16-
Flt3L melanoma. When the DC from untreated and Flt3L mice were compared by flow
cytometry in surface antigen expression (Suppl. Fig. 1 for gating conditions), the
populations from Flt3L mice were much more enriched in CD11c high cells, ∼95% vs.
∼25% in untreated mice (Fig. 1). The CD11c-selected population from Flt3L treated mice
was PDCA-1low, B220low but CD11chigh, indicating a paucity of plasmacytoid DC (Fig. 1).
The majority of the cells expressed MHC class II molecules, while the representation of the
CD8α and DEC-205 subset was increased relative to untreated mice. However in three
different experiments we observed that this increase was biased toward DEC-205+ DC over
CD8+ cells, possibly because of the presence of a recently described CD8α- CD24hi
population of precursors to CD8α+ DC [37].
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These results extend prior work on Flt3L [27] showing that the expansion induced by this
hematopoietin allows for an increase in the purity of CD11c selected cells that are also
enriched in DEC-205+ DC.
Spleen CD11c+ DC from Flt3L treated mice are functional antigen presenting cells
Since the DC generated from Flt3L treated mice expressed intermediate levels of I-Ab
molecules (Fig. 1), we expected that the cells would be functionally immature. A
distinguishing feature of mature DC is their capacity to stimulate naïve T cells in an
allogenic mixed leukocyte reaction (MLR). Thus we tested whether DC isolated from Flt3L-
treated mice exhibited allo-stimulatory activity, comparing it to untreated spleen DC (Fig.
2A). We evaluated the DC with or without direct in vivo activation with poly IC, which is
known to mature DC [38]. Accordingly, Flt3L or untreated CxB6 F1 mice were injected
with 50 μg of poly IC, and 15 h later, DC were enriched with anti-CD11c beads, fixed with
para-formaldehyde to prevent further maturation in culture, washed, and added in graded
doses to allogeneic T cells isolated from C57BL/6 mice, which had been labeled with CFSE.
In Fig. 2A, we show that both DC populations, upon in vivo maturation, stimulated CD4+
and CD8+ T cells to proliferate. We also found that the Flt3L-mobilized DC had a stronger
stimulating capacity being about 5 times more active than normal DC. This result can be
explained by the enrichment in CD11chigh cells in DC preparations from Flt3L treated mice.
Populations from Flt3L mice were almost entirely CD11chigh and MHC IIhigh DC, whereas
populations selected with anti-CD11 beads from normal spleen were roughly 30%
CD11chigh and MHC IIhigh DC and clearly had contaminating DX5+ and CD19+ NK and B
cells (Fig. 1).
To deliver HIV antigens to DC, Trumpfheller et al. cloned HIV gag p24 protein within the
heavy chain of a mAb specific for DEC-205 endocytic receptor [17]. We tested the ability of
the Flt3L DC to mediate presentation to HIV specific CD8+ and CD4+ T cells after in vitro
pulsing of DC with anti-DEC-205 HIV gag p24 fusion mAb (anti-DEC-p24) or a control Ig-
p24 fusion antibody. Specifically, CD11c+ populations were isolated from Flt3L treated and
non treated mice. Then the DC were cultured overnight with poly IC in the presence of the
indicated sources of gag antigen, washed to remove excess antigen and added to HIV gag
specific T cells for 6 h. We found (Fig. 2B) that both DC populations stimulated IFN-γ
production from HIV-gag primed CD8+ and CD4+ T cells isolated from mice primed with
Adenovirus-gag p24 and boosted with anti-DEC-p24 and poly IC. Adenovirus-p24 primarily
primes CD8+ T cells, while anti-DEC-p24 along with poly IC induces CD4+ T cells as
described by Trumpfheller et al. [17]. The response to DC pulsed with anti-DEC-p24 was
similar to a pool of pre-processed HIV gag 15 mer peptides, and anti-DEC-p24 antibody
resulted in stronger responses than control Ig-p24 (Fig. 2B). There was a small difference
between the DC from Flt3L treated mice and those from normal mice in their ability to
stimulate antigen-primed T cells. Thus, Flt3L treatment induced high numbers of CD11c+
DC that were functionally comparable to normal DC in their capacity to process and present
in vitro anti-DEC-p24 mAb.
Altogether these results demonstrate that CD11c selected DC isolated from Flt3L-mobilized
mice were functional in inducing MLR and in exogenous MHC class I and class II antigen-
presentation pathways.
Cross-presentation of anti-DEC-p24 is promoted by in vitro maturation of Flt3L CD11c+ DC
and restricted to DEC-205+ DC
Effective T cell stimulation only occurs if in parallel to antigen uptake, DC undergo
maturation, a process that can be triggered by different pathogens or mimics of microbial
agonists, such as poly IC for double stranded RNA or lipopolysaccaride respectively. In
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vitro studies have indicated that DC maturation leads to enhanced cross-presentation as well
as expression of the costimulatory molecules required for activation of CD8+ T cells
[30,39-42]. To confirm the capacity of maturation to promote cross-presentation, we
enriched splenic CD11c+ DC from mice treated with B16 Flt3L melanoma cells, added
different sources of HIV gag protein or peptides for 5 h, and then cultured the cells
overnight without or with 0.1 μg/ml of LPS or 25 μg/ml of poly IC as maturation stimuli.
After extensive washing, the cells were added to HIV gag specific T cells in the presence of
BFA, and cross-presentation was assessed 6 h later by intracellular cytokine staining for
IFN-γ secretion by CD8+ T cells.
In three different experiments (Fig. 3A), LPS or poly IC treatment improved cross-
presentation relative to PBS treated DC, although the latter could undergo spontaneous
maturation in culture as previously reported [43-46]. Although these results cannot be used
to assess if immature Flt3L-mobilized DC have any cross-presenting function for
stimulation of IFN-γ production from T cells, the results indicate that anti-DEC-p24 mAb is
efficiently cross-presented by more mature Flt3L DC, and all our subsequent studies used
poly IC to stimulate the antigen-pulsed Flt3L DC.
Splenic CD8α+ DEC-205+ DC are specialized to cross-present cell-associated and protein
antigens [4,19,21,25,47]. In Fig. 1 we have shown that CD8α+ DEC-205+ cell numbers
expanded considerably after Flt3L treatment with a profound increase skewed toward the
DEC-205+ subset (Fig. 1). To verify that DEC-205+ DC were responsible for DEC-205
mediated cross-presentation of HIV gag, CD11c+ DEC-205+ and CD11c+ DEC-205- cells
were purified and sorted by FACS from the spleens of mice inoculated with B16 Flt3L
melanoma cells (Methods and Suppl. Fig. 1). Sorted cells were pulsed with anti-DEC-p24,
then poly IC was added. After 15 h, graded doses of antigen-pulsed and matured DEC-205+
and DEC-205- cells were added to HIV gag primed T cells, and IFN-γ secretion was
assessed 6 h later.
Both DC subsets were able to stimulate CD8+ T cells to secrete IFN-γ after in vitro
incubation with a pool of HIV gag p24 15 mer peptides (Fig. 3B). However, when we
analyzed cross-presentation of gag protein within anti-DEC-p24 mAb, only the DEC-205+
DC efficiently cross-presented HIV gag to primed CD8+ T cells over a wide range of DC to
T cell doses, 1:10-1:90 (Fig. 3B). In contrast, there was no presentation of control Ig-p24,
indicating that the DEC+ DC subset selectively cross-presents DEC-targeted protein.
With these results, we proceeded to carry out quantitative assays to assess the efficiency of
HIV gag p24 cross-presentation by Flt3L-mobilized DC.
DEC-205 greatly increases the efficiency of HIV gag cross-presentation
To better evaluate the efficiency of cross-presentation by Flt3L-mobilized DC, we carried
out more detailed studies of antigen and DC dose. When we pulsed Flt3L CD11c+ DC with
different doses of anti-DEC-p24 vs control Ig-p24 overnight, along with maturation by poly
IC, escalating doses of anti-DEC-p24 resulted in an increased percentage of IFN-γ+ CD8+ T
cells, reaching a plateau at only 1 μg/ml of the fusion antibody (Fig. 4A). When used to
stimulate HIV gag primed T cells at a DC:T cell ratio of 1:3, the Flt3L DC pulsed with 0.1
μg/ml of anti-DEC-p24 induced higher levels of IFN-γ secretion by CD8+ T cells than DC
pulsed with 1 μg/ml control Ig-p24 (Fig. 4A). In Fig. 4B, we displayed the same results but
from 4 different experiments.
Next, we assessed the role of DC dose. Flt3L DC were pulsed with a fixed dose of control
Ig-p24 vs increasing concentrations of anti-DEC-p24 or gag peptides. After maturation with
poly IC, DC were added in graded numbers to HIV gag primed/boosted T cells. In vitro
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cross-presentation of anti-DEC-p24 by Flt3L DC occurred in a DC-dose dependent manner.
Flt3L DC pulsed with anti-DEC-p24 stimulated IFN-γ secretion of CD8+ T cells over a
range of DC to T cell doses from 1:3 up to 1:90 (Fig. 4C, left panel). A similar DC dose
dependence was obtained when we analyzed stimulation of CD4+ T cells after anti-DEC-
p24 in vitro pulsing (Fig. 4C, right panel).
Together the results indicate that a low concentration of anti-DEC-p24 antibody mediates
presentation of gag protein to both HIV specific CD8+ and CD4+ T cells in a DC-dose
dependent fashion.
DEC-205 targeting greatly enhanced cross-presentation of soluble HIV gag p24 protein
Previous studies showed that only relatively high doses of antigens e.g., 50-100 μg/ml OVA,
are able to bring about cross-presentation through the exogenous MHC-I pathway. We
therefore wondered if DEC targeting could increase presentation of protein that was not
coupled to the anti-DEC antibody. We first compared cross-presentation of anti-DEC-p24
mAb with soluble HIV gag p24 protein. In Fig. 5A we found that cross-presentation of
soluble HIV gag protein to specific CD8+ T cells by Flt3L DC took place in a dose
dependent manner, and that 25 μg/ml of gag was comparable to 1 μg/ml of anti-DEC-gag (or
0.25 μg/ml gag protein within the antibody). These results demonstrate that cross-
presentation of anti-DEC-p24 by Flt3L DC improves efficiency almost 100 times relative to
non-targeted gag protein.
Then to rule out a boosting effect of the anti-DEC antibody itself, we analyzed CD8+ T cell
responses to Flt3L DC pulsed in vitro with anti-DEC-p24 fusion mAb, unconjugated anti-
DEC-205 mAb, the combination of unconjugated anti-DEC-205 with HIV gag protein, or
the soluble HIV protein alone. As shown in Fig. 5B, the combination of unconjugated mAb
with soluble HIV protein did not enhance gag presentation.
We conclude that introduction of a protein within anti-DEC-205 antibody greatly enhances
the capacity of Flt3L-mobilized DC to cross-present a protective microbial antigen, HIV
gag.
Discussion
The limited number of DC isolated from mouse spleen has often restricted their use for
functional studies, particularly cross-presentation, where the relevant CD8α+ or DEC-205+
DC [4,19-21,47] represent a relatively small fraction of CD11c high DC. Flt3L is a regulator
of hematopoietic cell development and increases the number of peripheral DC in various
tissues of mice [26,36]. It is now evident that the receptor, Flt-3 or Flt-2 or CD135, is a
marker for committed progenitors of DC that form in the bone marrow and then continue to
respond to Flt3L after migration via the blood into spleen and lymph nodes [48-53].
Interestingly the expansion in DC numbers was skewed towards the expansion of DEC-205+
cells over CD8+ DC. The CD8- DEC-205+ DC may represent precursors to CD8+ DEC-205+
DC [37]. One emphasis of our current study is that when mice are exposed to Flt3L, it
becomes much more feasible to study cross-presentation, since the numbers and purity of
cross-presenting DEC-205+ DC are greatly expanded.
The majority of studies of cross-presentation emphasize the clonal expansion of CD8+ TCR
transgenic T cells. Polyclonal T cells from HIV gag primed mice also respond to cross-
presenting DC, although the efficiency of presentation was increased by targeting the gag
protein to the DEC-205 receptor. Previously we found that the targeting of HIV gag protein
to the DEC-205 receptor on monocyte-derived human DC enhanced cross-presentation to
gag-specific CD8+ T cells from individuals infected with HIV-1 [18]. In that study, we also
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compared different receptors, DEC-205, MMR and DC-SIGN, and obtained evidence that
antigen delivery via DEC-205 was superior to the other endocytic receptors for expanding
gag-specific CD8+ T cells [18]. Here our current studies were directed to DEC-205
targeting, where DEC-205 represents one receptor that is clearly expressed in vivo on most T
cell area DC of human lymph nodes [54]. Other DC receptors and surface products might be
expected to mediate improved presentation with antibody-targeted antigens. Here we
provide quantitative information on the capacity of DC to present antigen via DEC-205,
which also takes place in DC preparations that are abundant and highly enriched. Flt3L
induced expansion of DC should greatly facilitate studies of cross-presentation and set the
stage for the use of Flt3L to enhance the efficacy of DEC-205 targeted vaccines in vivo.
Immune responses require DC maturation induced by microbial molecular patterns, in
particular by agonists for microbial pattern recognition receptors [55]. These agonists may
directly enhance the intracellular mechanism for cross-presentation [29,40,42,56]. The role
of maturation is difficult to study with isolated DC because these undergo what is termed
“spontaneous” maturation in culture. Nevertheless, we were able to show that maturation of
Flt3L DC, either with LPS or with poly IC, improved cross-presentation of anti-DEC-p24.
Traditionally cross-presentation requires high doses of antigens with the most sensitive
protein, OVA, typically being used at concentrations of >50 μg/ml or 1 nM to detect a signal
even with OT-I TCR transgenic reporter T cells [33,57]. In our prior experience with mouse
DC, cross-presentation of OVA to OT-I T cells under similar culture conditions to the gag
experiments in our paper required concentrations of 60-250 μg/ml OVA [13]. Here, by using
the DEC-205 receptor to target the HIV gag protein to DC, we find that dose as low as 1 μg/
ml of anti-DEC-p24 or 5 pM leads to strong presentation to CD8+ T cells from a polyclonal
population. Also, relative to non-targeted gag p24 protein, DEC-205 mediated cross-
presentation is 100 fold more efficient. The quantitative aspects of our data highlight the
potential value that Flt3L mobilization and receptor mediated targeting potentially play in
the use of cross-presentation to present non-replicating antigens to CD8+ T cells.
While the goal of this paper is to highlight the usefulness of Flt3L-mobilized DC in cross-
presentation of a microbial protein, Flt3L mobilization may have a role in enhancing
presentation of DC targeted vaccines. Others have reported that daily injections of Flt3L
over a period of 9 days is able to expand DC numbers several fold in humans [58,59].
Further experiments are required to assess if there are ways to combine DC mobilization and
DC targeting to improve vaccination.
Materials and Methods
Mice
Balb/c × C57Bl/6 (C × B6) F1 mice from Harlan were maintained under specific pathogen-
free conditions and used at 6-8 wk of age in accordance with Rockefeller University Animal
Care and Use Committee guidelines.
B16 Flt3L melanoma cells
Melanoma cells expressing Fms-like tyrosine kinase 3 ligand (Flt3L), were established via
retroviral gene transfer [60] and generously provided by L. Santambrogio (Albert Einstein
College of Medicine, New York, NY). B16 Flt3L melanoma cells were cultured with
DMEM containing 10% FBS and 5 × 106 were injected s.c into the belly region of mice.
After 15-20 days, all major splenic DC subsets had expanded >10 fold as shown previously
[36] and reproduced here.
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Antibodies and reagents
We purchased from BD Biosciences FITC-antibodies to CD3ε (145-2C11), B220
(RA3-6B2), MHC-II (IAb) and DX5, PE- antibodies to CD8α (53-6.7), PDCA-1 and anti-
CD11c (HL3 clone), PerCP-anti-CD4 (RM4-5), PerCP-Cy5.5-anti-CD8α, PE-Cy 7 anti-
IFN-γ (XMG1.2), APC-antibodies anti-IFN-γ (XMG1.2) and thy 1.2 (CD 90.2, clone
53-2.1), Alexa Fluor 700 anti-CD3 (500A2), APC-Alexa 647-antibodies to DEC-205 and
B220 as well as Cytofix/Cytoperm kit and Stabilizing Fixative. Anti-CD11c beads (N418)
were from Miltenyi Biotec. Rat anti MHC class II (TIB120, M5/114.15.2) was from ATCC.
Anti-rat IgG Dynalbeads and Live/Dead Fixable Aqua vitality dye were from Invitrogen.
Polyinosinic-polycytidylic acid (poly IC) was from Thermo Scientific. Other reagents were
LPS from Escherichia coli 0127:B8 and BFA from Sigma-Aldrich.
Fusion HIV gag mAb
The fusion mAb anti-DEC-p24 and the control Ig-p24 were prepared as described [17] and
were characterized by SDS-PAGE and Western Blotting (HRP-conjugated anti-mouse IgG
or anti-HIV gag). Binding of the fusion mAb to stable DEC-205 transfected CHO cells was
tested by FACS analysis as described [17].
Soluble HIV gag p24 protein
The cDNA for the HIV gag p24 (clade B) was fused to the sequence containing a signal
peptide and a FLAG epitope tag. This construct named SF-p24 (GenBank accession number
GQ304738) was cloned into pCMV expression vector and stably transfected into CHO cells,
in order to produce a soluble, FLAG-tagged (SF) protein of gag p24, which was purified
without endotoxin contamination from the culture supernatants of CHO/SF-p24 cells, by
anti-FLAG® M1 Affinity Gel (Sigma-Aldrich, St. Louis, MO) following manufacturer's
instruction.
HIV gag peptide library
Overlapping (staggered by 4 aminoacids) 15 mer peptides spanning the entire HIV gag p17
or p24 sequence were synthesized by H. Zebroski in the Proteomics Resource Center (The
Rockefeller University). HIV gag p24 or p17 peptides were resuspended at 1 mg/ml of each
peptides in 100% DMSO and added to DC at 1 μg/ml.
Soluble HIV gag p24 protein
The cDNA for the HIV gag p24 (clade B) was fused to the sequence containing a signal
peptide and a FLAG epitope tag. This construct named SF-p24 (GenBank accession number
GQ304738) was cloned into pCMV expression vector and stably transfected into CHO cells,
in order to produce a soluble, FLAG-tagged (SF) protein of gag p24. The SF-p24 protein
was purified without endotoxin contamination from the culture supernatants of CHO/SF-p24
cells, by Anti-FLAG® M1 Affinity Gel (Sigma-Aldrich, St. Louis, MO) following the
manufacturer's instruction.
Cell preparation
Spleens were removed from Flt3L treated mice, cut in small fragments, and digested into
single cell-suspensions with 400 U/ml collagenase D (Roche Applied Science) for 25 min at
37°C. After inhibition of collagenase with 10 mM EDTA, the cells were resuspended in PBS
in 2 mM EDTA and 2% FCS. CD11c+ DC were enriched by positive selection using anti-
CD11c magnetic beads and MACS columns (Miltenyi Biotec). To purify CD8α+ and CD8α-
cells, CD11c+ cells were sorted on a FACSVantage (BD Biosciences) into B220- DX5-
CD3- CD11chigh CD8α+ and B220- DX5- CD3- CD11chigh CD8α- fractions. The purity of
the DC subsets was >95-99%. Antigen primed T cells, which were from F1 mice primed
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with Adenovirus gag and boosted 4-6 wks later with anti-DEC-p24 and poly IC, were
enriched by excluding MHC class II+ cells using TIB120/M5/114 rat mAb and anti-rat IgG
Dynalbeads.
Mixed leukocyte reaction (MLR) assay for DC maturation and function
B16 Flt3L treated or untreated CxB6 F1 mice were injected i.p. with PBS or 50 μg of poly
IC. Fifteen hours later spleens were collected and collagenase digested. CxB6 DC were
fixed for 20 min on ice and graded numbers were added to 3×105 CFSE labeled (Molecular
Probes, Eugene, OR) C57BL/6 T cells. After 4 days of culture, samples were stained with
Live/Dead Fixable Violet viability dye (Invitrogen, Carlsbad, CA), Alexa 700 anti-CD3,
APC Alexa 780 anti-CD8 and PerCP Cy 5.5 anti-CD4, and acquired on a BD LSR II flow
cytometer (BD Biosciences). Data were analyzed with FlowJo Software (Tree Star, Inc.).
Ag-presentation assay to HIV gag specific T cells
2×106 splenic CD11c+ DC, or purified DC subsets, were first pulsed with different antigens
(Results) for 5 h in 24-well culture plates in a final volume of 0.5 ml RPMI 1640 containing
5% FCS and the supernatant (3% vol/vol) from J558L cells transduced with murine GM-
CSF. Then 25 μg/ml poly IC or 0.1 μg/ml of LPS was added to the cultures for 15-18h. The
DC were washed three times with PBS and added to antigen-primed T cells. IFN-γ
production during a 6 h DC:T cell coculture in the presence of 10 μg/ml of BFA was
monitored by washing the cells, incubating 10 min at 4°C with 2.4G2 mAb to block FcγR,
and staining with Live/Dead Fixable Aqua, anti-CD3, anti-CD8 and anti-CD4 mAbs for 20
min at 4°C. Cells were fixed and permeabilized 10 min with Cytofix/Cytoperm and stained
with APC-conjugated anti-IFN-γ mAb for 15 min at room temperature and resuspended in
stabilizing fixative. 105 live-CD3+ events were acquired using a BD LSR II flow cytometer.
Data were analyzed with FlowJo Software.
Statistical analysis
Statistical significance was evaluated using two-tailed Student's t test, 95% confidence
interval. Results are expressed as means ± SD. In the figures, p values of 0.05 are labeled
with a single asterisk (*), 0.01 (**) or 0.001 (***). Analysis was performed with a Prism 3
program (Graphpad Sofware Inc.).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Cell surface markers of splenic CD11c+ DC by flow cytometry
Splenic CD11c+ cells were enriched by positive selection on anti-CD11c beads from CxB6
F1 mice that had been injected with B16 Flt3L melanoma cells or from untreated F1 mice. A
six-color flow cytometry panel was used to simultaneously analyze surface markers on
CD11c-selected cells. Appropriate isotype-matched, non-binding control Ig's were used to
set the quadrant lines (not shown). DC were analyzed by gating against low scatter debris,
followed by a live/dead exclusion gate. Analysis is representative of three independent
experiments that all examined pooled splenic DC from at least two mice.
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Figure 2. Comparision of antigen-presentation by Flt3L and untreated CD11c+ DC
(A) B16 Flt3L-injected or untreated CxB6 F1 mice were stimulated with 50 μg of poly IC
for 15 h and allo-stimulatory capacity of splenic CD11c+ DC was compared. Both
populations of DC were fixed with 1% para-formaldehyde, washed 3 times, and cultured at
various numbers in the presence of a constant number (3×105) of T cells enriched from
allogenic C57BL/6 mice. T cell proliferation was detected after 4 days of culture by CFSE
dilution of CD8+ and CD4+ T cells. Similar results were obtained using allogeneic T cells
from the SJL mouse strain. Data are representative of two independent experiments. (B)
Splenic CD11c+ cells purified from Flt3L or untreated F1 mice were pulsed in vitro for 4-5
h with anti-DEC-p24, control Ig-p24 at 0.1 and 1 μg/ml, p24 or p17 15-mer peptides mix (1
μg/ml), followed by 25 μg/ml of poly IC. Fifteen hours later, 1×106 washed DC were added
to 3×106 T cells for 6 h in the presence of BFA (10 μg/ml) to detect IFN-γ secretion by
intracellular cytokine staining. The T cells were isolated from F1 mice that were primed
with Adenovirus gag and boosted with anti-DEC-p24 and poly IC (Methods). Data show
mean ± SD of the percentage of CD8+ IFN-γ+ T cells (left) or CD4+ IFN-γ+ T cells (right)
representative of two independent experiments.
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Figure 3. Cross-presentation of anti-DEC-gag p24 is enhanced by poly IC and is restricted to
DEC-205+ DC
(A) Splenic Flt3L-mobilized CD11c+ DC were pulsed in vitro with 0.1 and 1 μg/ml of anti-
DEC-p24, control Ig-p24, or p24 or p17 15-mer peptides (1 μg/ml). Five hours later,
medium or LPS (0.1 μg/ml) or poly IC (25 μg/ml) were added. After overnight culture, the
yields of cells were comparable. The cells were washed and added for 6 h to HIV gag
primed T cells at a ratio of 1:3 with 10 μg/ml BFA. Data show mean ± SD percentage of
CD8+ IFN-γ+ T cells pooled from three independent experiments. *p<0.05, paired Student's
t-test, 1 μg/ml of anti-DEC-p24 vs. 1 μg/ml of control-Ig-p24 after maturation with poly IC.
(B) CD11c+ cells from mice injected with B16 Flt3L melanoma cells were enriched by
MACS positive selection and then separated into DEC-205+ and DEC-205- CD11chigh DC
subsets by FACS. Sorted cells were washed and pulsed with either medium, anti-DEC-p24
vs. control Ig-p24 at 0.1 or 1 μg/ml, or p24 vs p17 peptides at 1 μg/ml. Five hours later,
without washing off the antigens, poly IC at 25 μg/ml was added. After 15 h, graded doses
of DEC-205+ and DEC205- cells (x-axis for DC:T cell ratio) were added to 3×106 HIV gag
primed T cells, and IFN-γ secretion was assessed by intracellular cytokine staining 6 h later.
Frequencies of CD8+ IFN-γ+ T cells from two independent experiments are shown after
stimulation by DEC-205+ (left panel) and DEC-205- cells (right panel).
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Figure 4. Efficient gag-presentation to CD8+ and CD4+ T cells following in vitro targeting of
Flt3L DC with anti-DEC-gag p24 mAb
(A) Splenic Flt3L CD11c+ DC pulsed with anti-DEC-p24, control Ig-p24, p24 or p17
peptides at the concentration indicated, matured overnight with poly IC 25 μg/ml were used
to stimulate IFN-γ secretion by HIV gag primed T cell in a 6 h assay at 1:3 DC: T cell ratio.
Dot plots are representative of three independent experiments. (B) As in A, but Flt3L DC
were pulsed with limiting dilutions of anti-DEC-p24 and control Ig-p24, matured with poly
IC and cocultured for 6 h with primed HIV gag T cells. IFN-γ secretion from CD8+ T cells
and CD4+ T cells was assessed by intracellular cytokine staining. Data show mean ± SD for
the percentage of CD8+ IFN-γ+ T cells (left) or CD4+ IFN-γ+ T cells (right) from four
independent experiments. (C) Graded doses of Flt3L DC, pulsed and matured as described
in B, were cocultured for 6 h with primed HIV gag T cells (x-axis for DC:T cell ratio). IFN-
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γ secretion from CD8+ T cells (left) and CD4+ T cells (right) was assessed by intracellular
cytokines. Mean ± SD of the frequencies of IFN-γ producing CD8+ and CD4+ T cells in
three to four independent experiments are indicated.
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Figure 5. Conjugation of DEC-205 to HIV gag, but not DEC-205 itself, greatly enhances cross-
presentation of soluble HIV gag p24 protein
(A) Splenic Flt3L CD11c+ DC were pulsed with 1 μg/ml of anti-DEC-p24 or increasing
doses of HIV gag p24 soluble protein. The DC were matured with 25 μg/ml poly IC and
added at various doses to stimulate primed HIV gag T cells in a 6 h coculture (x-axis for
DC:T cell ratio). IFN-γ secretion from CD8+ T cells was assessed by intracellular cytokine
staining. Data show mean ± SD of three independent experiments. (B) Splenic Flt3L
CD11c+ DC were pulsed with 1 μg/ml of anti-DEC-p24, or 1 μg/ml of unconjugated anti-
DEC, or different combinations of HIV gag p24 protein and unconjugated anti-DEC, or
limiting doses of HIV gag p24 protein. As above, the DC were matured with poly IC and
added at various doses to stimulate primed HIV gag T cells in a 6 h coculture (x-axis for
DC:T cell ratio). IFN-γ secretion from CD8+ T cells was assessed by intracellular cytokine
staining. Data show mean ± SD of two independent experiments. *p<0.05, **p<0.01, paired
Student's t-test; 1 ug/ml of anti-DEC-p24 vs. other samples.
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